Investing.comCodex · 实盘不做把握 6/10
北京时间·🕒 发布 04:04:37时区推断·⟳ 抓取 04:06:50·⚡ 决策 07-23 04:11:57 +5m07s·96.7 天前
Verastem启动VS-7375在KRAS G12D非小细胞肺癌二期试验首例给药
VS-7375在TARGET-D 202二期试验完成首例患者给药，适应症为既往治疗后的KRAS G12D突变晚期非小细胞肺癌。
📄 原文Investing.com↗ 原文
Verastem doses first patient in lung cancer trial for VS-7375
Wall Street makes small moves ahead of closely-watched tech earnings for AI cues BOSTON - Verastem Oncology (NASDAQ:VST…
不做 Verastem Oncology（VSTM.US）
二期首例给药是研发进度而非数据读出或获批，短期收入增量为零，生物科技交易edge不足，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-22 · 扩散 low · price-in 风险 medium ↗
关键理由
- VS-7375在TARGET-D 202二期试验完成首例患者给药，适应症为既往治疗后的KRAS G12D突变晚期非小细胞肺癌。
- 美国每年约1万名非小细胞肺癌患者携带KRAS G12D突变，约占非小细胞肺癌5%，目前该人群无FDA批准的KRAS G12D靶向疗法。
- 但这是二期试验启动节点，不是读出、获批或商业化里程碑，对近期收入贡献为零。
主要风险
- 临床开发仍处早中期，疗效和安全性需等后续数据验证；同类小盘生物科技首例给药新闻常缺少可持续资金承接。
原文全文
展开原文 · 2,163 字
Wall Street makes small moves ahead of closely-watched tech earnings for AI cues
BOSTON - Verastem Oncology (NASDAQ:VSTM) has dosed the first patient in its TARGET-D 202 Phase 2 trial evaluating VS-7375 in patients with previously treated KRAS G12D-mutated advanced non-small cell lung cancer, according to a press release statement issued today.
The trial will evaluate VS-7375 as monotherapy at 900mg daily in patients with unresectable locally advanced or metastatic KRAS G12D-mutated non-small cell lung cancer whose disease progressed following prior treatment with platinum-based chemotherapy and anti-PD-(L)1 therapy. A cohort in the study will also evaluate VS-7375 in patients with asymptomatic untreated brain metastases.
VS-7375 is an investigational oral KRAS G12D inhibitor designed to bind to both the active and inactive states of KRAS G12D. The TARGET-D 202 trial represents the second registration-directed Phase 2 trial for VS-7375, following the TARGET-D 201 trial in metastatic pancreatic cancer that began dosing patients in June.
Approximately 10,000 patients with non-small cell lung cancer harbor a KRAS G12D mutation in the U.S. annually, representing about 5% of non-small cell lung cancer cases. No therapies specifically targeting KRAS G12D are currently approved by the FDA for this patient population.
In June 2026, the FDA granted Fast Track Designation to VS-7375 for the treatment of adult patients with KRAS G12D-mutated unresectable locally advanced or metastatic non-small cell lung cancer who have received platinum-based chemotherapy and an anti-PD-(L)1 antibody.
Verastem initiated TARGET-D 101, a Phase 1/2 trial evaluating VS-7375, in June 2025. The company reported that VS-7375 demonstrated anti-tumor activity across multiple KRAS G12D-driven tumor types with a manageable safety profile. The company expects to share an update in the second half of 2026.
Verastem is developing VS-7375 through a collaboration with GenFleet Therapeutics, which retains rights in mainland China, Hong Kong, Macau, and Taiwan.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
BOSTON - Verastem Oncology (NASDAQ:VSTM) has dosed the first patient in its TARGET-D 202 Phase 2 trial evaluating VS-7375 in patients with previously treated KRAS G12D-mutated advanced non-small cell lung cancer, according to a press release statement issued today.
The trial will evaluate VS-7375 as monotherapy at 900mg daily in patients with unresectable locally advanced or metastatic KRAS G12D-mutated non-small cell lung cancer whose disease progressed following prior treatment with platinum-based chemotherapy and anti-PD-(L)1 therapy. A cohort in the study will also evaluate VS-7375 in patients with asymptomatic untreated brain metastases.
VS-7375 is an investigational oral KRAS G12D inhibitor designed to bind to both the active and inactive states of KRAS G12D. The TARGET-D 202 trial represents the second registration-directed Phase 2 trial for VS-7375, following the TARGET-D 201 trial in metastatic pancreatic cancer that began dosing patients in June.
Approximately 10,000 patients with non-small cell lung cancer harbor a KRAS G12D mutation in the U.S. annually, representing about 5% of non-small cell lung cancer cases. No therapies specifically targeting KRAS G12D are currently approved by the FDA for this patient population.
In June 2026, the FDA granted Fast Track Designation to VS-7375 for the treatment of adult patients with KRAS G12D-mutated unresectable locally advanced or metastatic non-small cell lung cancer who have received platinum-based chemotherapy and an anti-PD-(L)1 antibody.
Verastem initiated TARGET-D 101, a Phase 1/2 trial evaluating VS-7375, in June 2025. The company reported that VS-7375 demonstrated anti-tumor activity across multiple KRAS G12D-driven tumor types with a manageable safety profile. The company expects to share an update in the second half of 2026.
Verastem is developing VS-7375 through a collaboration with GenFleet Therapeutics, which retains rights in mainland China, Hong Kong, Macau, and Taiwan.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。